The Drug Controller General of India (DCGI) is assessing the utilization of substitute drugs to treat the fungal infection mucormycosis as a shortage of Amphotericin B, the medicine commonly used for the infection, has been reported due to the wide spread of the disease.
“In a bid to bridge the gap between demand and supply, while this is the preferred drug, the drug regulator is looking at alternatives especially those drugs which are used to treat Kala Azar. The decision is likely to come soon,” a source close to the developments told the Economic Times.
On the other hand, the central government is also simultaneously contemplating rolling out a clinical management protocol along with the appropriate guidelines for the use of Amphotericin B. The overall idea is to use this drug only in severe cases and employ alternative medicines to treat the lesser severe cases.
Mucormycosis is reported to give rise to organ dysfunction, blindness and turn out to be quite fatal in the absence of timely treatment.
Certain experts also reportedly consider the overuse of steroid whilst treating Covid-19 patients as one of the reasons behind the emergence of black fungus though others believe that diabetic patients are more susceptible to fall prey to the same.
Comments ↓
An Appeal...
Dear Reader,
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.
